메뉴 건너뛰기
New England Journal of Medicine
Volumn 369, Issue 15, 2013, Pages 1475-1476
Pancreatic atrophy - A new late toxic effect of sorafenib
Author keywords

[No Author keywords available]
Indexed keywords

EID: 84885644574     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1305302     Document Type: Letter
Times cited : (33)
References (5)
  • 2
    • 84855177596 scopus 로고    scopus 로고
    • Sorafenib-induced diarrhea and hypophosphatemia: Mechanisms and therapeutic implications
    • Mir O, Coriat R, Boudou-Rouquette P, Durand JP, Goldwasser F. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012;23:280-1.
    • (2012) Ann Oncol , vol.23 , pp. 280-281
    • Mir, O.1    Coriat, R.2    Boudou-Rouquette, P.3    Durand, J.P.4    Goldwasser, F.5
  • 3
    • 55049136730 scopus 로고    scopus 로고
    • Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
    • Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-96.
    • (2008) Oncologist , vol.13 , pp. 1084-1096
    • Hutson, T.E.1    Figlin, R.A.2    Kuhn, J.G.3    Motzer, R.J.4
  • 4
    • 77949888608 scopus 로고    scopus 로고
    • Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study
    • Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010;28:1054-60.
    • (2010) J Clin Oncol , vol.28 , pp. 1054-1060
    • Antoun, S.1    Birdsell, L.2    Sawyer, M.B.3    Venner, P.4    Escudier, B.5    Baracos, V.E.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.